Literature DB >> 2445909

Protective immunisation against hepatitis B with an internal antigen of the virus.

K Murray1, S A Bruce, P Wingfield, P van Eerd, A de Reus, H Schellekens.   

Abstract

Preparations of hepatitis B virus (HBV) core antigen (HBcAg) synthesised in Escherichia coli have been shown previously to confer partial immunity against infection by the virus [Murray, Bruce, Hinnen, Wingfield, van Eerd, de Reus, and Schellekens: EMBO Journal 3:645-650, 1984]. In a further experiment reported here, immunisation of chimpanzees with a similar preparation of HBcAg that had been treated with sodium dodecyl sulphate in order to expose e antigen epitopes was found to protect one animal completely and another quite substantially upon challenge with the virus. The results are used to support the argument for trials in humans of a vaccine against HBV based upon or containing HBcAg and its e antigen derivative, and in discussion of a more general role for internal antigens in generating immunity against viral infection.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2445909     DOI: 10.1002/jmv.1890230202

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  15 in total

Review 1.  The chimpanzee model for hepatitis B virus infection.

Authors:  Stefan F Wieland
Journal:  Cold Spring Harb Perspect Med       Date:  2015-06-01       Impact factor: 6.915

2.  Immunogenicity of peptide fusions to hepatitis B virus core antigen.

Authors:  S J Stahl; K Murray
Journal:  Proc Natl Acad Sci U S A       Date:  1989-08       Impact factor: 11.205

3.  Chimeric rabbit/human Fab antibodies against the hepatitis Be-antigen and their potential applications in assays, characterization, and therapy.

Authors:  Xiaolei Zhuang; Norman R Watts; Ira W Palmer; Joshua D Kaufman; Altaira D Dearborn; Joni L Trenbeath; Elif Eren; Alasdair C Steven; Christoph Rader; Paul T Wingfield
Journal:  J Biol Chem       Date:  2017-08-23       Impact factor: 5.157

4.  Identification of immunodominant T cell epitopes of the hepatitis B virus nucleocapsid antigen.

Authors:  C Ferrari; A Bertoletti; A Penna; A Cavalli; A Valli; G Missale; M Pilli; P Fowler; T Giuberti; F V Chisari
Journal:  J Clin Invest       Date:  1991-07       Impact factor: 14.808

5.  Characterization of T-cell response to woodchuck hepatitis virus core protein and protection of woodchucks from infection by immunization with peptides containing a T-cell epitope.

Authors:  S Menne; J Maschke; T K Tolle; M Lu; M Roggendorf
Journal:  J Virol       Date:  1997-01       Impact factor: 5.103

6.  Protection against woodchuck hepatitis virus (WHV) infection by gene gun coimmunization with WHV core and interleukin-12.

Authors:  R García-Navarro; B Blanco-Urgoiti; P Berraondo; R Sánchez de la Rosa; A Vales; S Hervás-Stubbs; J J Lasarte; F Borrás; J Ruiz; J Prieto
Journal:  J Virol       Date:  2001-10       Impact factor: 5.103

7.  Bicistronic woodchuck hepatitis virus core and gamma interferon DNA vaccine can protect from hepatitis but does not elicit sterilizing antiviral immunity.

Authors:  Jinguo Wang; Shashi A Gujar; Lucyna Cova; Tomasz I Michalak
Journal:  J Virol       Date:  2006-11-01       Impact factor: 5.103

8.  Hybrid hepatitis B virus core-pre-S proteins synthesized in avirulent Salmonella typhimurium and Salmonella typhi for oral vaccination.

Authors:  F Schödel; S M Kelly; D L Peterson; D R Milich; R Curtiss
Journal:  Infect Immun       Date:  1994-05       Impact factor: 3.441

9.  Murine immune response to HIV-1 p24 core protein following subcutaneous, intraperitoneal and intravenous immunization.

Authors:  L Fyfe; J Maingay; A C Robinson; S E Howie
Journal:  Immunology       Date:  1991-11       Impact factor: 7.397

10.  The position of heterologous epitopes inserted in hepatitis B virus core particles determines their immunogenicity.

Authors:  F Schödel; A M Moriarty; D L Peterson; J A Zheng; J L Hughes; H Will; D J Leturcq; J S McGee; D R Milich
Journal:  J Virol       Date:  1992-01       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.